Burkholderia pseudomallei Infections (Melioidosis) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Burkholderia pseudomallei Infections (Melioidosis) – Pipeline Review, H2 2017’, provides an overview of the Burkholderia pseudomallei Infections (Melioidosis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Burkholderia pseudomallei Infections (Melioidosis)

The report reviews pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Burkholderia pseudomallei Infections (Melioidosis) therapeutics and enlists all their major and minor projects

The report assesses Burkholderia pseudomallei Infections (Melioidosis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Burkholderia pseudomallei Infections (Melioidosis) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bavarian Nordic A/S

Emergent BioSolutions Inc

Grifols SA

MerLion Pharmaceuticals Pte Ltd

Soligenix Inc

Syntiron LLC

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Burkholderia pseudomallei Infections (Melioidosis) - Overview 6

Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 11

Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Assessment 12

Assessment by Target 12

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development 20

Bavarian Nordic A/S 20

Emergent BioSolutions Inc 20

Grifols SA 21

MerLion Pharmaceuticals Pte Ltd 21

Soligenix Inc 22

Syntiron LLC 22

Burkholderia pseudomallei Infections (Melioidosis) - Drug Profiles 24

ARD-3100 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

ARD-3150 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Burkholderia pseudomallei vaccine - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Burkholderia vaccine - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

EV-035 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

finafloxacin - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

GC-072 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

melioidosis vaccine - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

SGX-943 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecules for Infectious Diseases - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects 46

Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products 47

Burkholderia pseudomallei Infections (Melioidosis) - Product Development Milestones 48

Featured News & Press Releases 48

Jun 28, 2017: MerLion and Dstl Awarded DTRA Grant to Explore the Use of Finafloxacin against Biological Threat Agents 48

May 31, 2016: FDA Grants Soligenix “Fast Track” Designation for SGX943 for the Treatment of Melioidosis 48

Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC 49

Aug 14, 2014: US DTRA to fund preclinical work on Evolva’s antibiotic GC-072 49

Feb 21, 2014: Bavarian Nordic’s MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development 50

Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis 50

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

List of Tables

Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products under Development by Universities/Institutes, H2 2017 9

Products under Development by Companies, H2 2017 10

Products under Development by Universities/Institutes, H2 2017 11

Number of Products by Stage and Target, H2 2017 13

Number of Products by Stage and Mechanism of Action, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Burkholderia pseudomallei Infections (Melioidosis) – Pipeline by Bavarian Nordic A/S, H2 2017 20

Burkholderia pseudomallei Infections (Melioidosis) – Pipeline by Emergent BioSolutions Inc, H2 2017 21

Burkholderia pseudomallei Infections (Melioidosis) – Pipeline by Grifols SA, H2 2017 21

Burkholderia pseudomallei Infections (Melioidosis) – Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2017 22

Burkholderia pseudomallei Infections (Melioidosis) – Pipeline by Soligenix Inc, H2 2017 22

Burkholderia pseudomallei Infections (Melioidosis) – Pipeline by Syntiron LLC, H2 2017 23

Burkholderia pseudomallei Infections (Melioidosis) – Dormant Projects, H2 2017 46

Burkholderia pseudomallei Infections (Melioidosis) – Discontinued Products, H2 2017 47

List of Figures

List of Figures

Number of Products by Targets, H2 2017 12

Number of Products by Stage and Targets, H2 2017 12

Number of Products by Mechanism of Actions, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Type, H2 2017 18

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports